BTKis for CLL: Module

CME

BTK Inhibitor Therapy for Patients With CLL: A Global Perspective

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: March 13, 2023

Expiration: March 12, 2024

Toby A Eyre
Toby A Eyre, MBChB, MD

Activity

Progress
1
Course Completed
Introduction

In this activity, Toby Eyre, MBChB, MD, discusses best practices in the use of BTK inhibitors for patients with chronic lymphocytic leukemia (CLL), including adverse event (AE) management and current treatment paradigms.

Please note that the key points discussed in this activity are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity, and some questions in this activity will be asked twice: once before the discussion that informs the best choice and then again after that specific discussion. Your responses will be aggregated for analysis, but your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with CLL do you provide care for in a typical month?

Presurvey 1

A patient with CLL experiences a grade 2 arthralgia (first occurrence) 8 months after starting treatment with an approved BTK inhibitor. In your current practice, how would you modify BTK inhibitor therapy for this patient?

Presurvey 2

In the phase III ELEVATE-RR and ALPINE trials, which compared acalabrutinib with ibrutinib or zanubrutinib with ibrutinib for patients with previously treated CLL, which of the following is TRUE regarding rates of any-grade atrial fibrillation?